# Introduction

The main clinical question of phase I study is to find the maximum tolerated dose (MTD) of investigational treatments, in order to establish the safe and appropriate dose level that could be used in the following phase II trial. The critical part of finding MTD in phase I is that the number of participants in phase I study are usually just in dozens, and investigators need to efficiently locate the true MTD with limited samples and within short trial window, this process calls for accurate and transparent trial design which can accommodate flexible and versatile clinical settings in real-world. 
The most traditional and widely used methods to find MTD is 3+3 design, under which, cohorts of three participants are assigned a set of dose level, if 1/3 is experiencing DLT (Dose Limiting Toxicities), then another cohort of three participants is give the same level of dose; If more than 2/3 or 2/6 DLTs are observed, then terminate the trial and declare the dose below current is MTD; Otherwise, continue the trial and escalate the dose level for next cohort. As the adaptive design getting utilized in clinical trials, more and more novel phase I methods have been introduced, such as continual reassessment method (CRM), Bayesian Optimal Interval Design (BOIN), Modified Toxicity Probability Interval Design (mTPI), Escalation with overdose control (EWOC), Bayes Logistic Regression Model (BLRM), etc. 
The focus of this project is BOIN, a method introduced by Liu and Yuan in 2015, which belongs to the class of model-assisted designs. Comparing to 3+3 and other adaptive design methods, BOIN yields a very good performance in simulation (close to CRM), but is much more transparent and easy to implement in real trials, so it becomes one of the most popular adaptive design in practice. BOIN design can be used to evaluate MTD of single-agent trials and drug-combination trials. Generally speaking, BOIN assumes the DLT occurance count y_j given observed DLT rate p_j and total number n_j follows a binomial distribution, and p_j follows a beta distribution, so the posterior distribution of p_j bases on a beta-binomial model. According to the model, investigators can pre-set a DLT rate boundaries; when the real DLT rate p_j below or exceed the boundaries, the next dose level will repectively be de-escalated or escalated. As soon as the safety stopping rule being violated or reaching its max sample size, the trial will be terminated, and MTD will be estimated from trial data. In addition, for drug-combination trials, inverstigators can use BOIN to find a single MTD or MTD contour depending on their interests,  which are also known as BOIN-COMB and BOIN-waterfall design, using the same algorithms as above.

# Clinical Setting

A real clinical context is set for this project, which is borrowed from Gandhi and Bahledaâ€™s study. In a phase I study of neratinib in combination with temsirolimus in treating patients with HER2 dependent solid tumors, BOIN will be used to find a single MTD. The dose level in this study for neratinib is as $\{120,160,200,240\}$ mg, and for temsirolimus is $\{15,25,50,75\}$ mg. Neratinib is a tyrosine kinase inhibitor, binds to EGFR, HER2 and HER4, approved by FDA to treat early stage HER2-overexpressed/amplified breast cancer, whose recommended dose is 240 mg orally per day. Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR) kinase, approved by FDA to treat advanced renal cell carcinoma, whose recommended dose is 25 mg by infusion per week. The combination of both drugs can inhibit both mTOR and HER2, thus inhance the anti-tumor effect on patients with HER2 dependent solid tumors.

# Methodology

## Design Parameters

$$
\begin{aligned}
\{A_1<A_2\cdots<A_J\}:& \text{dose set of drug A}\\
\{B_1<B_2\cdots<B_K\}:& \text{dose set of drug B}\\
A_jB_k:& \text{current drug combination }\\
n_{jk}: & \text{total number of participants at dose} A_jB_k\\
y_{jk}: & \tetx{number of participants having DLT as dose} A_jB_k\\
p_{jk}: & \text{observed DLT rate}\\
&=\frac{y_{jk}}{n_{jk}}\\
N_{max}: & \text{maximum sample size}
\phi : & \text{desired DLT}\\
\phi_1: & \text{lower DLT boundary}\\
\phi_2: & \text{upper DLT boundary}\\
\lambda_e: & \text{lower DLT rate boundary}\\
&=\frac{ln(\frac{1-\phi_1}{1-\phi})}{ln(\frac{\phi(1-\phi_1)}{\phi_1(1-phi)})}\\
\lambda_d: & \text{upper DLT rate boundary}\\
&=\frac{ln(\frac{1-\phi}{1-\phi_2})}{ln(\frac{\phi_2(1-\phi)}{\phi(1-phi_2)})}\\
A_E: & \text{dose escalating set}\\
&=\{A_{j+1}B_k,A_jB_{k+1}\}\\
A_D: & \text{dose de-escalating set}\\
&=\{A_{j-1}B_k,A_jB_{k-1}\}\\
\end{aligned}
$$

## Trial Design

The BOIN-COMB shares the same essence as BOIN single drug, except for that during escalation and de-escalation we have to pick one drug combination from two choices. We give cohorts of participants with starting dose level of drug combination, when observed DLT rate $p_{jk}$ at current drug combination is smaller than $\lambda_e$, then we escalating the next dose level to $A_E$, and pick the combination with the largest probability that DLT rate falls in $(\lambda_e, \lambda_d)$; similarly, when $p_{jk}$ is larger than $\lambda_d$, then we de-escalating the next dose level to $A_D$, and pick the combination with the largest probability that DLT rate falls in $(\lambda_e, \lambda_d)$; If $p_{jk} \in (\lambda_e, \lambda_d)$ then retain current dose level and continue next cohort. Trial will be terminated if reach maximum sample size $N_{max}$ or excess safe toxicity.

## Trial Schema

To better illustrate the trial procedure, here's the flow-chart of BOIN-COMB:


